The Zhitong Finance App learned that Xiaomo released a research report stating that the minimally invasive robot B (02252) was given a “increase in holdings” rating, and the target price dropped slightly from HK$60 to HK$59.9. As the only company in the world to cover five major surgical specialties, the company's programs include laparoscopy, orthopedics, full vascular, natural foramen, and percutaneous surgery.

The bank expects the number of laparoscopic and joint replacement surgical robots installed in China to increase rapidly by 10 to 50 times, respectively, in 2020-26. As a leading enterprise, I believe minimally invasive robots will be in an advantageous position to benefit from this growing trend. Furthermore, it is predicted that the Group's revenue will grow at a compound annual rate of 161% in the 2023-27 fiscal year, and balance of payments will be achieved in 2025. Furthermore, the company had a strong start after listing, then was sold off and stabilized. The bank believes that there is still room for the stock to rise further in the future.